Turning Point Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|
| Revenue | $30.8M | $25.0M | — | — |
| Operating income | −$238.0M | −$62.6M | −$14.1M | −$25.6M |
| Net income | −$236.6M | −$60.7M | −$13.5M | −$24.8M |
| Total assets | $1.00B | $1.14B | $422.2M | $103.3M |
| Total liabilities | — | — | — | — |
| Equity | $954.4M | $1.11B | $404.4M | −$48.4M |
| EPS (diluted) | — | — | — | — |
| Shares out. | 49.0M | 35.9M | 35.9M | 3.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −772.0%
- Net margin
- −767.3%
- Return on equity
- −24.8%
- Return on assets
- −23.6%
- Return on capital (ROCE)
- −24.9%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $19.49
- Revenue growth (YoY)
- 23.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Accruals / assets
- −8.2%clean
- Piotroski F-Score
- 2/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 2 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2024-01-08Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
- Phase 1/2Recruitingreadout ~2026-09-30A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Phase 1/2Recruitingreadout ~2028-02-29A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsAug 17, 2022
- Results of operationsAug 8, 2022
- Entered a material agreementJun 24, 2022
- Shareholder voteJun 21, 2022
- Entered a material agreement · Director / officer changeJun 3, 2022
- Other material eventJun 3, 2022
- Results of operations · Other material eventMay 10, 2022
- Entered a material agreementMay 5, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GAug 29, 2022
- EFFECTAug 22, 2022
- 4FORM 4 SUBMISSIONAug 17, 2022
- 4FORM 4 SUBMISSIONAug 17, 2022
- 4FORM 4 SUBMISSIONAug 17, 2022
- 4FORM 4 SUBMISSIONAug 17, 2022
- 4FORM 4 SUBMISSIONAug 17, 2022
- 4FORM 4 SUBMISSIONAug 17, 2022
- 4FORM 4 SUBMISSIONAug 17, 2022
- 4FORM 4 SUBMISSIONAug 17, 2022
- 4FORM 4 SUBMISSIONAug 17, 2022
- 4FORM 4 SUBMISSIONAug 17, 2022
- 4FORM 4 SUBMISSIONAug 17, 2022
- S-8 POSAug 17, 2022
- S-8 POSAug 17, 2022
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.